Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialEnriqueta Felip, Heather A. Wakelee, Alexander Luft et al.|The Lancet|2021Cited by 1.5k
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trialEnriqueta Felip, H. Wakelee, Nasser K. Altorki et al.|Annals of Oncology|2023Cited by 251
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).Heather A. Wakelee, Enriqueta Felip, Nasser K. Altorki et al.|Journal of Clinical Oncology|2021Cited by 117